A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-28. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In 2015, they collaborated with the electronics company HTC to develop the HTC Vive, a virtual reality headset released in 2016. Valve's president, Gabe Newell, aimed for Valve to become more like Nintendo, which develops games in tandem with hardware, allowing them to create innovative games such as Super Mario 64 (1996). In 2016, Valve released The Lab, a collection of VR minigames, and recognized that many players wanted a more ambitious VR AAA game. Walker wondered if they could develop a VR "killer app" equivalent to the influential FPS Doom in 1993.
), as shown by the equations. The distribution coefficient is calculated as the ratio between the concentration of the metal cations in the organic and aqueous phase, whereas the separation factor is calculated as the ratio between the two distribution coefficients.
=== Alternative stop codons === There are variations on the standard genetic code, and alternative stop codons have been found in the mitochondrial genomes of vertebrates, Scenedesmus obliquus, and Thraustochytrium.
== Safety == As an oxidant, silver nitrate should be properly stored away from organic compounds. It reacts explosively with ethanol. Despite its common usage in extremely low concentrations to prevent gonorrhea and control nosebleeds, silver nitrate is still very toxic and corrosive. Brief exposure will not produce any immediate side effects other than the purple, brown or black stains on the skin, but upon constant exposure to high concentrations, side effects will be noticeable, which include burns. Long-term exposure may cause eye damage. Silver nitrate is known to be a skin and eye irritant. Silver nitrate has not been thoroughly investigated for potential carcinogenic effect.
A more recent preparation method pioneered by the Royal Ontario Museum removes all bones for a complete skeleton while also producing a round skin without bill or legs (called a ROM, though if one set of wing and leg bones remain with the skin the preparation is called a shmoo in North America). Alternatively, the entire bird (or any soft parts associated with preparations described above) may be preserved in alcohol. For any of these methods, several supplemental preparations may be made. For example, a wing may be removed and preserved separately as a spread wing for better study of flight feathers; a tissue sample may be removed and frozen for molecular analyses; or a recording of the bird's song before collection may be archived. Neither molecular samples nor sound recordings require a bird to be collected (killed). Finally, if the bird is too rotten for the skin and feathers to be preserved, as is the case with some salvaged specimens, the skeleton alone may be preserved. Dried tissue is removed from skeletons by using dermestid beetle larvae (genus Dermestes). Whereas in the past arsenic was routinely added to skins to protect them from destruction by insects, specimens prepared today are generally protected by an initial freezing period to kill insects and their eggs followed by keeping them in high-quality museum cases in a climate-controlled room. Each specimen has data associated with it, and the amount of data available is usually directly correlated with the specimen's scientific value.
Sources: en.wikipedia.org
== Genetics == LADA appears to share genetic risk factors with both T1D and T2D, including susceptibility loci related to HLA-associated immune function as well as loci associated with insulin resistance, but is genetically distinct from both. Within the LADA patient group, a phenotypic heterogeneity has been observed with varying degrees of insulin resistance and autoimmunity. As a result, LADA is considered a heterogeneous and complex genetic disorder.
=== Wilson's disease === Wilson's disease is a rare autosomal (chromosome 13) recessive genetic disorder of copper transport that causes an excess of copper to build up in the liver. This results in liver toxicity, among other symptoms. The disease is now treatable. Wilson's disease is produced by mutational defects of a protein that transports copper from the liver to the bile for excretion. The disease involves poor incorporation of copper into ceruloplasmin and impaired biliary copper excretion and is usually induced by mutations impairing the function of the Wilson copper ATPase. These genetic mutations produce copper toxicosis due to excess copper accumulation, predominantly in the liver and brain and, to a lesser extent, in kidneys, eyes, and other organs. The disease, which affects about 1/30,000 infants of both genders, may become clinically evident at any time from infancy through early adulthood. The age of onset of Wilson's disease ranges from 3 to 50 years of age. Initial symptoms include hepatic, neurologic, or psychiatric disorders and, rarely, kidney, skeletal, or endocrine symptomatology. The disease progresses with deepening jaundice and the development of encephalopathy, severe clotting abnormalities, occasionally associated with intravascular coagulation, and advanced chronic kidney disease. A peculiar type of tremor in the upper extremities, slowness of movement, and changes in temperament become apparent.
=== ColdFusion and Java === The standard ColdFusion installation allows the deployment of ColdFusion as a WAR file or EAR file for deployment to standalone application servers, such as Macromedia JRun, and IBM WebSphere. ColdFusion can also be deployed to servlet containers such as Apache Tomcat and Mortbay Jetty, but because these platforms do not officially support ColdFusion, they leave many of its features inaccessible. As of ColdFusion 10 Macromedia JRun was replaced by Apache Tomcat. Because ColdFusion is a Java EE application, ColdFusion code can be mixed with Java classes to create a variety of applications and use existing Java libraries. ColdFusion has access to all underlying Java classes, supports JSP custom tag libraries, and can access JSP functions after retrieving the JSP page context (GetPageContext()). Prior to ColdFusion 7.0.1, ColdFusion components could only be used by Java or .NET by declaring them as web services. However, beginning in ColdFusion MX 7.0.1, ColdFusion components can now be used directly within Java classes using the CFCProxy class. Recently, there has been much interest in Java development using alternate languages such as Jython, Groovy and JRuby. ColdFusion was one of the first scripting platforms to allow this style of Java development.
== SJ == SJ (s) Svalbard and Jan Mayen (ISO 3166 digram) (i) Societas Iesu (Latin: The Society of Jesus, the Jesuit order) (i) Statens Järnvägar (Swedish State Railways) SJA – (i) Staff Judge Advocate (military law) SJC – (i) Supreme Judicial Court of Massachusetts (note: the highest court in the state of Maine is also called the Supreme Judicial Court) SJM – (s) Svalbard and Jan Mayen (ISO 3166 trigram) SJW – (i) Social Justice Warrior
Frederic Durán-Jordà established one of the earliest blood banks during the Spanish Civil War in 1936. Duran joined the Transfusion Service at the Barcelona Hospital at the start of the conflict, but the hospital was soon overwhelmed by the demand for blood and the paucity of available donors. With support from the Department of Health of the Spanish Republican Army, Duran established a blood bank for the use of wounded soldiers and civilians. The 300–400 mL of extracted blood was mixed with 10% citrate solution in a modified Duran Erlenmeyer flask. The blood was stored in a sterile glass enclosed under pressure at 2 °C. During 30 months of work, the Transfusion Service of Barcelona registered almost 30,000 donors, and processed 9,000 liters of blood. In 1937 Bernard Fantus, director of therapeutics at the Cook County Hospital in Chicago, established the first hospital blood-bank in the United States. In setting up a hospital laboratory that preserved, refrigerated and stored donor blood, Fantus originated the term "blood bank". Within a few years, hospital and community blood-banks were established across the United States. Until the middle of World War II, the newly established US blood banks rejected African-American donors. During the war, Black people were allowed to donate blood, but the donated blood was labeled as being suitable only for transfusion into another person from the same race.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.